{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.5","upperLimit":"20.8","value":"10.1"},{"groupId":"OG001","lowerLimit":"2.8","upperLimit":"14.6","value":"7.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"description":"Median progression free survival (PFS) is where PFS are assessed from the time of randomization to first evidence of disease recurrence or death of any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Galinpepimut-S + Montanide + GM-CSF","id":"OG000","title":"Galinpepimut-S"},{"description":"Montanide + GM-CSF","id":"OG001","title":"Control"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 5 years and 11 months","title":"Progression-free Survival","type":"PRIMARY","unitOfMeasure":"months"}